{"filing":{"accession_number":"0001193125-26-243074","cik":"0000899460","ticker":"MNKD","company_name":"MANNKIND CORP","form":"8-K","filing_date":"2026-05-28","report_date":null,"primary_document":"mnkd-20260527.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526243074/mnkd-20260527.htm"},"events":[{"id":8402,"run_id":7378,"accession_number":"0001193125-26-243074","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The filing discloses a material regulatory milestone: on May 27, 2026, the FDA released MannKind from a five-year postmarketing requirement to conduct a large randomized controlled trial (8,000-10,000 patients) assessing pulmonary malignancy risk with Afrezza. This removal of a significant regulatory burden is favorable to the company and would affect a reasonable investor's assessment of Afrezza's regulatory pathway and commercial prospects. The disclosure also updates clinical trial progress (INHALE-1st enrollment expansion) and a pending pediatric BLA with a May 29, 2026 PDUFA date. While this is primarily a positive regulatory/clinical update rather than a discrete event type (not a restatement, impairment, covenant breach, or other specific category), the material nature of the FDA's release from the postmarketing requirement warrants classification as a material event.","company_name":"MANNKIND CORP","ticker":"MNKD","filing_date":"2026-05-28","form":"8-K","submitted_at":null,"items":[{"id":2275,"accession_number":"0001193125-26-243074","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material regulatory milestone: on May 27, 2026, the FDA released MannKind from a five-year postmarketing requirement to conduct a large randomized controlled trial (8,000-10,000 patients) assessing pulmonary malignancy risk with Afrezza. This removal of a significant regulatory burden is favorable to the company and would affect a reasonable investor's assessment of Afrezza's regulatory pathway and commercial prospects. The disclosure also updates clinical trial progress (INHALE-1st enrollment expansion) and a pending pediatric BLA with a May 29, 2026 PDUFA date. While this is primarily a positive regulatory/clinical update rather than a discrete event type (not a restatement, impairment, covenant breach, or other specific category), the material nature of the FDA's release from the postmarketing requirement warrants classification as a material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:19:29.179950+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2275,"accession_number":"0001193125-26-243074","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The filing discloses a material regulatory milestone: on May 27, 2026, the FDA released MannKind from a five-year postmarketing requirement to conduct a large randomized controlled trial (8,000-10,000 patients) assessing pulmonary malignancy risk with Afrezza. This removal of a significant regulatory burden is favorable to the company and would affect a reasonable investor's assessment of Afrezza's regulatory pathway and commercial prospects. The disclosure also updates clinical trial progress (INHALE-1st enrollment expansion) and a pending pediatric BLA with a May 29, 2026 PDUFA date. While this is primarily a positive regulatory/clinical update rather than a discrete event type (not a restatement, impairment, covenant breach, or other specific category), the material nature of the FDA's release from the postmarketing requirement warrants classification as a material event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-29T02:19:29.179950+00:00","company_name":"MANNKIND CORP","ticker":"MNKD","filing_date":"2026-05-28"}]}